# EDGAR Filing Document

**Accession Number:** 0001829247
**File Stem:** 0001493152-26-013684
**Filing Date:** 2026-3
**Character Count:** 41074
**Document Hash:** 256e16829bbca39b97b0af340759e83d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-013684.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001493152-26-013684

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260327

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BullFrog AI Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001829247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844786155
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41600
- **FILM NUMBER:** 26814424

**BUSINESS ADDRESS:**
- **STREET 1:** 325 ELLINGTON BLVD.
- **STREET 2:** UNIT 317
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878
- **BUSINESS PHONE:** 3013672055

**MAIL ADDRESS:**
- **STREET 1:** 325 ELLINGTON BLVD.
- **STREET 2:** UNIT 317
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 27, 2026

**BULLFROG AI HOLDINGS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-41600** | **84-4786155** |
| (State or other jurisdiction of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**325 Ellington Blvd, Unit 317**

**Gaithersburg, MD 20878**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(240) 658-6710**

**Not Applicable**

*(Former name or former address, if changed since last report)*

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.00001<br> per share | BFRG | The Nasdaq Stock Market LLC<br> (The Nasdaq Capital Market) |
| Tradeable Warrants | BFRGW | The Nasdaq Stock Market LLC<br> (The Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry Into a Material Definitive Agreement.**

On March 27, 2026, BullFrog AI Holdings, Inc. (the "Company") entered into a Feasibility Agreement (the "Agreement") with a global pharmaceutical company (the "Client"). Pursuant to the Agreement, the Company will apply its proprietary methodology and artificial intelligence and machine learning tool, bfLEAP®, to discover and provide the Client with prioritized drug target candidates, associated causal gene networks with target near-neighbors unblinded, and target dossiers for advancement-ready drug candidates for major depressive disorder (MDD). The Agreement will remain in full force and effect for one year from the execution of the Agreement.

In connection with the Agreement, the Company is eligible to receive pre-determined milestone payments upon the delivery of certain deliverables to the Client. The Client will have the option to receive the exclusive right to use a selected "final target" drug candidate for its research and development purposes for a period of three years.

The Client may terminate the Agreement without cause upon thirty days' notice to the Company, and either party may terminate the Agreement immediately on written notice of a breach of the Agreement that remains uncured for thirty days following receipt of notice of such breach from the non-breaching party.

The Agreement also contains customary representations, warranties and covenants, including with respect to intellectual property, as well as provisions relating to indemnification, confidentiality and other matters.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the redacted text of the Agreement, a copy of which is filed (with certain portions redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K) as Exhibit 10.1 hereto and incorporated by reference herein.

**Item 8.01. Other Matters.**

On March 30, 2026, the Company issued a press release announcing the entry into the Agreement. A copy of the press release is attached hereto and incorporated herein by reference as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are being furnished herein:

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 10.1\*# | [Feasibility Agreement, dated as of March 27, 2026, by and between BullFrog AI Holdings, Inc. and Client.](ex10-1.htm) |
| 99.1 | [Press release, dated March 30, 2026.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

\* Portions of this exhibit have been redacted in accordance with Regulation S-K Item 601(b)(10)(iv). The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.

# Schedules and certain exhibits have been omitted pursuant to Regulation S-K Item 601(b)(2). The Company agrees to furnish supplementally any omitted schedules and exhibits to the SEC upon its request.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 30, 2026 | **BullFrog AI Holdings, Inc.** | **BullFrog AI Holdings, Inc.** |
|  | By: | */s/ Vininder Singh* |
|  | Name: | Vininder Singh |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE OMITTED PORTIONS OF THIS DOCUMENT ARE INDICATED BY [\*\*\*].**

**FEASIBILITY AGREEMENT**

[\*\*\*] and its affiliates ("<u>[\*\*\*]</u>") desire to retain BullFrog AI Holdings, Inc. ("<u>Company</u>"), with an address of 325 Ellington Blvd. #317 Gaithersburg, Md 20878, for performance of Feasibility Services (as defined below) pursuant to the terms and conditions of this Feasibility Agreement ("<u>Agreement</u>").

1. <u>Feasibility Services</u>. Company shall perform the activities detailed in the description of services
 attached hereto as **Exhibit A** (Description of Feasibility Services), which may be amended
 in writing by the parties at any time (the " <u>Feasibility Services</u> ").

2. <u>Company Obligations; Contacts</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Company
 represents and warrants that each individual performing Feasibility Services hereunder is
 an employee, consultant, or approved subcontractor of Company. Company (i) shall cause each
 such employee, consultant or approved subcontractor performing under this Agreement to abide
 by the applicable terms and conditions hereunder, and (ii) will be liable for the acts and
 omissions of such employees, consultants, or approved subcontractor.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Company
 shall perform the Feasibility Services consistent with the state of current data quality
 and integrity research principles, AI/ML best practices, and shall observe safe and diligent
 handling procedures of Deliverables.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Company's
 contact(s) with [\*\*\*] is [\*\*\*], email [\*\*\*].com, or whomever [\*\*\*] may designate in writing.
 [\*\*\*]'s contact(s) with Company is Vin Singh[\*\*\*] or whomever Company may designate in writing.

3. <u>Reports, Deliverables</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) As
 [\*\*\*] may request, and as may be set forth in **Exhibit A** (Description of Feasibility
 Services), Company shall keep [\*\*\*] regularly advised on the progress of the Feasibility
 Services in a format that is mutually agreed upon between the parties (collectively " <u>Progress Reports</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;(b) Company
 shall deliver to [\*\*\*] (i) Feasibility assessment of Dentate Gyrus for MDD samples as defined
 in the Exhibit A; (ii) list of targets prioritized by Company ("Target List"),
 (iii) unblinded networks with tractability assessments for [\*\*\*] Preselected Targets ("Target
 Network"), and Final Target with associated Target Network (collectively " <u>Deliverables</u> "
 described in detail in Exhibit A) according to the process and details set forth in Section
 10(c).

4. <u>Compensation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) In
 consideration for Company's performance of the Feasibility Services described in this
 Agreement, [\*\*\*] shall pay Company an amount not to exceed the amount set forth in **Exhibit A** (Description of Feasibility Services). [\*\*\*] shall pay Company within ninety (90) days
 of [\*\*\*]'s receipt and approval of an invoice. Unless otherwise set forth in **Exhibit A,** all invoices must be submitted by Company within forty-five (45) days of performance
 of the related Feasibility Services hereunder. In the event of termination of this Agreement
 by [\*\*\*] without cause, [\*\*\*] shall pay Company for Feasibility Services performed and, as
 applicable, expenses incurred through the date of termination in accordance with the budgeted
 amounts set forth in **Exhibit A** and invoice approval terms of this **Section 4**.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Company
 understands that the terms and conditions of this Agreement, including, but not limited to,
 the name or other information of Company and Company's employees performing the Feasibility
 Services, and the amount of any payment made hereunder, may be disclosed and made public
 by [\*\*\*] as required by law or regulation, industry code, or as agreed by the parties, including
 those disclosures of transfers of value as between [\*\*\*] and Company required for the purposes
 of relevant transparency rules. Company hereby consents to the collection, processing, and
 disclosure of Company's employees' personally identifiable information to the
 extent required under any such law, regulation, or code. For the purposes of collection,
 processing and disclosure, [\*\*\*] may transfer such information outside the United States
 and European Union. As reasonably requested by [\*\*\*], Company agrees to cooperate in good
 faith with [\*\*\*] to promptly provide accurate and complete information in connection with
 payments made to or by the Company in relation to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The
 final payment to be made under this Agreement may be accompanied by a financial reconciliation,
 taking into account the payment to be made in accordance with this **Section 4** and,
 only after the performance of all Feasibility Services contemplated hereunder, the delivery
 to [\*\*\*] of all Reports described in **Section 3** (Reports, Deliverables) of this Agreement
 and the return of all items described in **Section 8** (Confidential Information) of this
 Agreement. If, at the time of such financial reconciliation, the total amount [\*\*\*] has paid
 is less than the amount to which Company is entitled hereunder, [\*\*\*] shall pay the amount
 due Company at such time. Any overpayment due [\*\*\*] pursuant to this Agreement, as determined
 at the time of final reconciliation, will be made payable to [\*\*\*], within forty-five (45)
 days of [\*\*\*]'s notice to Company of such overpayment and sent to: [\*\*\*], along with
 an explanation for such payment and accompanying support documentation for the remittance
 with a copy to the [\*\*\*] contact set forth in **Section 2** (Company Obligations; Contacts)
 of this Agreement.

Feasibility Services Agreement CONFIDENTIAL 1

&nbsp;&nbsp;&nbsp;&nbsp;(d) Company
 shall maintain, at no additional charge to [\*\*\*], in accordance with generally accepted accounting
 principles, complete and accurate records related to: (i) amounts billed to and payments
 made by [\*\*\*] hereunder and (ii) expenses incurred on behalf of and reimbursed by [\*\*\*] hereunder.
 Company shall provide [\*\*\*] supporting documentation concerning any disputed invoice or payment
 within thirty (30) days after [\*\*\*] advises Company of a dispute. Payments made hereunder
 will be subject to final adjustment as determined by such review. Company shall retain such
 records for a period of three (3) years from the termination or expiration of this Agreement
 or the length of time as may be required by any federal, state or local law, ordinance or
 regulation, whichever period is longer.

&nbsp;&nbsp;&nbsp;&nbsp;(e) Company
 acknowledges and agrees that [\*\*\*] is providing compensation under this Agreement based on
 Company's particular skills and experience and is not offering Company this fee on
 the grounds of any official or governmental position Company may hold.

&nbsp;&nbsp;&nbsp;&nbsp;(f) When
 required by any applicable law or regulation, [\*\*\*] will deduct withholding tax from any
 amounts otherwise due Company under this Agreement and remit such amounts to any relevant
 tax authority. Any such amounts deducted by [\*\*\*] shall be treated as having been paid by
 [\*\*\*] to Company for purposes of this Agreement. Company and [\*\*\*] shall cooperate in good
 faith to qualify any amounts due Company under this Agreement for any applicable reductions
 of, or exemptions from, withholding tax under any applicable law or regulation.

5. <u>Electronic Data</u>. If performance of the Feasibility Services under this Agreement involves the recording
 or transmittal to [\*\*\*] of electronic data, Company shall comply with the electronic data
 obligations set forth in **Exhibit B** attached hereto, as applicable, as well as any
 restrictions or obligations arising under applicable data protection laws. Company shall
 maintain reasonable administrative, technical, and physical safeguards and other security
 measures commensurate, as applicable, with the types of confidential information being processed,
 created, stored, transmitted, or archived by Company for or on behalf of [\*\*\*].

6. <u>Term and Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) This
 Agreement will be effective upon full execution by the parties (" <u>Effective Date</u> ")
 and will be effective for a period of one (1) year thereafter (" <u>Term</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;(b) [\*\*\*]
 may terminate this Agreement without cause upon thirty (30) days' notice to Company.
 If [\*\*\*] is paying compensation to Company in relation to the Feasibility Services, in the
 event of [\*\*\*]'s termination of this Agreement without cause, [\*\*\*] will compensate
 Company for (i) all Feasibility Services actually performed in accordance with the terms
 of this Agreement, and (ii) all reasonable non-cancellable expenses actually incurred by
 Company in relation to the Feasibility Services. Notwithstanding the above, for no reason
 will [\*\*\*] be obligated to pay Company an amount in excess of the "Total Compensation
 (not to exceed)" amount set forth in **Exhibit A**.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Either
 party may terminate this Agreement immediately upon written notice to the other party in
 the event of a material breach by the other party of any provision of this Agreement that
 remains uncured thirty (30) days following receipt of notice of such breach from the non-breaching
 party. Termination or expiration of this Agreement will not affect any rights or obligations
 which have accrued prior to termination thereof, or any other rights or remedies provided
 at law or equity which either party may otherwise have.

7. <u>Acceptance Procedures; Failure to Perform</u>. [\*\*\*] acknowledges and agrees that, in the performance
 of the Feasibility Services, Company shall be required to perform the Feasibility Services
 in accordance with this Agreement and applicable professional and scientific standards, but
 that Company cannot guarantee a particular outcome. Company is responsible for the quality,
 technical accuracy and completeness of Feasibility Services and Deliverables furnished to
 [\*\*\*].

Feasibility Services Agreement CONFIDENTIAL 2

8. <u>Confidential Information</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) At
 all times during the Term and for a period of ten (10) years following termination or expiration
 of this Agreement in its entirety, Company shall, and shall cause its officers, directors,
 employees and agents to, keep confidential and not publish or otherwise disclose to a third
 party and not use, directly or indirectly, for any purpose, any Confidential Information
 furnished or otherwise made known to it, directly or indirectly, by [\*\*\*], except to the
 extent such disclosure or use is expressly permitted by the terms of this Agreement. "Confidential
 Information" means all information or data provided orally, visually, in writing or
 other form by or on behalf [\*\*\*] (or an Affiliate or representative of [\*\*\*]) to Company
 (or to an Affiliate or representative of Company) in connection with this Agreement, including
 the list of **Preselected Targets**, the identity of [\*\*\*]'s choice of the **Final Target**, and, the scientific, regulatory or business affairs or other activities of [\*\*\*],
 or except any portion thereof which:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) has
 been published by a third party or otherwise is or hereafter becomes part of the public domain
 by public use, publication, general knowledge or the like through no wrongful act, fault,
 or negligence on the part of Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) has
 been in Company's prior to disclosure by [\*\*\*] without any obligation of confidentiality
 with respect to such information; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) is
 subsequently received by Company from a third party without restriction and without breach
 of any agreement between such third party and [\*\*\*];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) in
 each of (i), (ii) and (iii), as shown by Company's written records.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon
 the earlier of completion of the Feasibility Services or termination, Company shall return
 to [\*\*\*] or destroy all Confidential Information as directed by [\*\*\*]. Notwithstanding anything
 contained in **Section 19** (Dispute Resolution) of this Agreement, the parties hereto
 agree that in the event of Company's breach of this **Section 11**, [\*\*\*] will be
 entitled to seek injunctive relief from any court of competent jurisdiction, without proof
 of damages, in addition to any other remedies that may be available at law or equity to [\*\*\*].

&nbsp;&nbsp;&nbsp;&nbsp;(c) If,
 in the reasonable opinion of Company's counsel, any Confidential Information is required
 to be disclosed pursuant to law, regulation or court order, Company shall give [\*\*\*] prompt,
 written notice (and in any case at least five (5) days' notice) in order to allow [\*\*\*]
 to take whatever action it deems necessary to protect its Confidential Information. In the
 event that no protective order or other remedy is obtained, or [\*\*\*] waives compliance with
 the terms of this **Section 8**, Company shall furnish only that portion of the Confidential
 Information which Company is advised by counsel as being legally required and shall notify
 [\*\*\*] in writing of the Confidential Information disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;(d) Company
 shall not disclose to [\*\*\*] any information which is confidential or proprietary to a third
 party without first obtaining the written consent of both such third party and [\*\*\*].

&nbsp;&nbsp;&nbsp;&nbsp;(e) Company
 Confidential Information: Information disclosed or generated by Company under this Agreement
 will be subject to the Bilateral Confidential Disclosure Agreement entered into by the partes
 and dated on or about October 21, 2025 (the " <u>NDA</u> "), in addition to the
 supplemental confidentiality provisions of this Agreement. Company Pre-existing Intellectual
 Property is Confidential Information of Company under the NDA. Subject to the provisions
 of Sections 10(c) and 10(d), the Target Network, the Preselected Targets, the Final Target
 and the Target Networks are Confidential Information of Company.

9. <u>Data Privacy and Protection</u>. Company shall comply with the provisions set forth in **Exhibit D** (Data Privacy and Protection). Company's obligations under **Exhibit D** (Data
 Privacy and Protection) shall survive termination or expiration of this Agreement.

10. <u>Ownership; Intellectual Property; Inventions; Review Period and Targets</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Pre-Existing Intellectual Property</u>. It is recognized and understood that certain pre-existing inventions
 and technologies owned prior to execution of this Agreement or developed independently of
 the Feasibility Services are the separate property of [\*\*\*] or Company and are not affected
 by this Agreement. Neither party shall have any claims to or rights in such separate inventions
 and technologies of the other party. Such pre-existing inventions and technologies owned
 or independently developed by Company shall be " <u>Company Pre-existing Intellectual Property</u>.".

&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Inventions</u>.
 " <u>Inventions</u> " shall mean any information, inventions, innovations, ideas,
 discoveries or products (whether or not copyrightable or patentable), suggestions, communications,
 correspondence, notes, Reports, all data, records, evaluations, or work products which are
 conceived, derived, reduced to practice, made or developed by a party as a result of conducting
 the Feasibility Services. Inventorship of Inventions shall be determined according to U.S.
 patent laws. During the performance of Feasibility Services, Company will develop Target
 List and Target Network, which will collectively remain Company Inventions.

&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Review Period.</u> Company will share the Target List with [\*\*\*]. [\*\*\*] shall have ninety (90) days
 after disclosure of the Target List ("Review Period") to review the available
 information and nominate 10 targets ("Preselected Targets") for access to the
 Target Network associated with those targets. Company agrees not to share or disclose Preselected
 Targets with any third party until expiration of the Review Period (subject to Section 10.(d)
 below). Upon conclusion of the Review Period, [\*\*\*] may nominate the target for further development
 ("Final Target"). The selection and names of Preselected Targets will be [\*\*\*]
 Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Target Exclusivity Term .</u> In the event [\*\*\*] choses one (1) Final Target and pay Company a one-time
 "Target Exclusivity Fee", Company hereby agrees not to disclose the Final Target
 and its Target Network to any third party for the duration of three (3) years ("Target
 Exclusivity Term"). During Target Exclusivity Term, [\*\*\*] shall have the right to use
 Final Target for any business purposes, except [\*\*\*] will not sell the Final Target and Associate
 Network to any third party during that time.

Feasibility Services Agreement CONFIDENTIAL 3

11. <u>Presentations and Publications</u>. Company shall not present or publish, or submit for publication, any
 work resulting from the Feasibility Services that references or relates to [\*\*\*]'s
 Confidential Information.

12. <u>Publicity</u>.
 Company shall not disclose the existence or terms of this Agreement or use [\*\*\*]'s
 name, trademarks, trade names, servicemarks or logos in any publicity, advertising, or announcement,
 without [\*\*\*]'s prior written consent, except, subject to section 8.(c), as required
 by law including U.S. securities laws.

13. <u>Representations, Warranties and Covenants</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Each
 party represents and warrants that: neither this Agreement nor any payment hereunder is in
 exchange for any explicit or implicit agreement or understanding that Company purchase, lease,
 order, prescribe, recommend or otherwise arrange for, or provide formulary or other preferential
 or qualifying status for the use of [\*\*\*] products; and the total payment for the Feasibility
 Services under this Agreement represents the fair market value for the Feasibility Services
 and has not been determined in any manner that takes into account the volume or value of
 any referrals or business between Company and [\*\*\*].

&nbsp;&nbsp;&nbsp;&nbsp;(b) Company
 represents, warrants, and covenants that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) in performance of Company's obligations under this Agreement, Company does and will comply with all applicable existing and future federal, state and local laws, regulations, ordinances and guidance documents, including, but not limited to laws, regulations and guidelines and other rules related to anti-bribery and anti-corruption, privacy and data protection, tax, immigration and healthcare programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Company has or shall obtain, and shall keep effective any licenses, certifications, permits or registrations necessary for Company to provide the Feasibility Services and Deliverables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Company does and will comply with all requirements regarding reporting and management of conflicts of interest and performance of Feasibility Services does not represent a conflict of interest;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Company is not and will not become a party to any contract with any third party which prohibits Company from performing its obligations under this Agreement or limits Company's ability to fulfill the terms of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) the Feasibility Services and any Deliverables provided under this Agreement will be conducted and produced in accordance with relevant scientific and professional standards and will be free from any security interest or other lien or similar encumbrance;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Except
 as expressly set forth in this Agreement, the Feasibility Services and the Deliverables are
 provided "as is" and Company disclaims all other warranties, express or implied.

14. <u>Debarment and Exclusion</u>. Company represents, warrants and covenants that it is not, and will not
 engage, directly or indirectly, any person to perform Feasibility Services under this Agreement
 if that person has ever been, is currently, or, to the best of Company's knowledge,
 is the subject of a proceeding that could lead to that person becoming, as applicable, (a)
 debarred by the FDA under 21 U.S.C. § 335a; (b) excluded, debarred, suspended, or otherwise
 ineligible to participate in the Federal health care programs or in Federal procurement or
 non-procurement programs; (c) listed on the FDA's Disqualified and Restricted Lists
 for clinical investigators; or (d) convicted of a criminal offense that falls within the
 scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended,
 or otherwise declared ineligible. In the event that Company receives notice of, or otherwise
 becomes aware of, the debarment, proposed debarment or such other exclusion, suspension,
 restriction or sanction of itself or any person providing Feasibility Services in connection
 with the performance of this Agreement, Company shall notify [\*\*\*] immediately and [\*\*\*]
 shall have the right to immediately terminate this Agreement.

15. <u>Independent Contractor</u>. The relationship of the parties under this Agreement is that of independent
 contractors. Nothing contained in this Agreement is intended or is to be construed so as
 to constitute the parties as partners, joint venturers, or one party as an agent or employee
 of the other party. Neither party has any express or implied right under this Agreement to
 assume or create any obligation on behalf of or in the name of the other party or to bind
 the other party to any contract, agreement or undertaking with any third party, and no conduct
 of a party will be deemed to imply such right. To the extent Company engages the services
 of any individual to support the Feasibility Services under this Agreement, Company is responsible
 for compliance with any applicable employment or tax laws.

Feasibility Services Agreement CONFIDENTIAL 4

16. <u>Assignment.</u> Neither party shall assign this Agreement nor any part thereof, without the prior written
 consent of the other party; provided, however, [\*\*\*] may assign this Agreement to one of
 its subsidiaries or parent entities without such consent; and additionally, [\*\*\*]
 may assign this Agreement to one of its affiliate entities or to a successor in interest
 to all or substantially all of its assets to which this Agreement relates, without such consent.
 Any attempted assignment in breach of this section will be null and void. Any permitted assignee
 shall assume all obligations of its assignor under this Agreement. No assignment shall relieve
 any party of responsibility for the performance of any accrued obligation, which such party
 then has hereunder.

17. <u>Notices</u>.
 Any notices required or permitted under this Agreement must be in writing and refer specifically
 to this Agreement, and must be sent by recognized national or international overnight courier,
 confirmed facsimile transmission (provided that duplicative copy is provided via confirmed
 electronic mail, registered mail or certified mail), confirmed electronic mail, or registered
 or certified mail, postage prepaid, return receipt requested, or delivered by hand to the
 address as set forth herein. Notices under this Agreement will be deemed to be duly given:
 (a) when delivered by hand; (b) upon confirmed electronic mail transmission; (c) two days
 after deposit with a recognized national or international courier; or (d) on the delivery
 date indicated in the return receipt for registered or certified mail. A party may change
 its contact information immediately upon written notice to the other party in the manner
 provided in this **Section 17**.

---

| | |
|:---|:---|
| **If to Company**:<br> Phone: [\*\*\*]<br> Fax: [\*\*\*]<br> Email: [\*\*\*] |  |
| **If to [\*\*\*]:** | **with a copy to:** |
| [\*\*\*] | [\*\*\*] |

---

18. <u>Indemnification</u>.
 Company agrees to indemnify, and hold [\*\*\*] and its affiliates, employees, directors, officers
 and agents harmless against any liability, judgment, demand, action, suit, loss, damage,
 cost and other expense (including, but not limited to, reasonable attorneys' fees to
 consider, advise and defend, and court costs) arising from and against any third party suit
 or claim made or proceedings brought against [\*\*\*] arising directly or indirectly out of
 (a) Company's or its employees' or agents' gross negligence, recklessness
 or willful misconduct, (b) breach by Company of any term of this Agreement including but
 not limited to, the representations and warranties set forth in this Agreement; (c) an assertion
 or allegation that the Deliverables constitute an infringement of any patent, copyright,
 trademark, trade dress, or any other intellectual property right; or (d) injury to a person
 (including death) or damage to property caused by Company, its employees or agents.

19. <u>Dispute Resolution</u>. If a dispute arises between the parties, the parties shall follow the provisions
 provided for in the Alternative Dispute Resolution attached hereto as **Exhibit C**.

20. <u>Survival</u>.
 Termination or expiration of this Agreement for any reason will not affect any rights or
 obligations which have accrued prior thereto, nor any such rights or obligations which are
 meant to survive termination of the Agreement.

21. <u>Severability</u>.
 If any provision, right or remedy provided for herein is held to be unenforceable or inoperative
 by a court of competent jurisdiction, the validity and enforceability of the remaining provisions
 will not be affected thereby.

22. <u>Waiver</u>.
 No waiver may be implied from conduct or failure to enforce rights. No provisions of this
 Agreement will be deemed waived by [\*\*\*] unless such waiver is in writing and signed by the
 authorized representative of [\*\*\*]. Waiver by [\*\*\*] of any default by Company of any provision
 of this Agreement will not be deemed a waiver of any subsequent or other default.

23. <u>Counterparts</u>.
 This Agreement may be executed in any number of counterparts, each of which will be deemed
 to be an original, and all of which together will constitute one and the same agreement.
 Each party acknowledges that an original signature or a copy thereof transmitted by facsimile
 or by PDF will constitute an original signature for purposes of this Agreement.

24. <u>Miscellaneous</u>.
 This Agreement includes all attached exhibits, all of which are herein incorporated by reference.
 This Agreement contains the entire understanding of the parties with respect to the subject
 matter hereof and supersedes all previous agreements and undertakings with respect thereto.
 This Agreement may be modified only by written agreement signed by the parties. Unless otherwise
 specifically set forth herein, no term hereunder serves to limit a party's rights to
 seek any applicable remedies available to it under law or equity. This Agreement will be
 construed, governed, and interpreted in accordance with the laws of the state of Illinois,
 excluding its conflicts of law provisions.

***Signature page follows***

Feasibility Services Agreement CONFIDENTIAL 5

**IN WITNESS WHEREOF**, each of the parties has caused this Agreement to be executed by its authorized representative in its name and on its behalf.

---

| | |
|:---|:---|
| [\*\*\*] | BullFrog AI Holdings, Inc. |
| By: | By: |
| Name: | Name: |
| Title: | Title: |
| Date: | Date: |

---

Feasibility Services Agreement CONFIDENTIAL 6

## Exhibit 99.1

**Exhibit 99.1**

**BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder**

*Commercial agreement serves as high-profile third party validation of BullFrog AI's proprietary capabilities*

 

*Agreement utilizes BullFrog AI's end-to-end analytical AI platform to accelerate drug discovery and development program*

 

GAITHERSBURG, Md., March 30, 2026 — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue ("Customer"), to apply the Company's proprietary bfLEAP<sup>®</sup> platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate. The MDD market was valued at more than $8 billion in 2025 and expected to grow at an average annual rate of nearly 5% to reach in excess of $11 billion by 2032, according to Stellar Market Research.

"This agreement represents strong, high-quality validation of our proprietary capabilities from a leading industry partner, and we are confident that this relationship will expand across other areas of the Customer's research and development portfolio," said BullFrog AI Founder and CEO Vin Singh. "Our platform provides drug developers with an end-to-end analytical tool engineered to resolve multimodal biological complexity at scale. Our bfLEAP<sup>®</sup>, bfPREP™, and bfARENAS<sup>TM</sup> integrated platform leverages causal network inference to provide drug developers a clearer path forward in the discovery and characterization of drug targets for complex disease like MDD. We look forward to continuing to build on our successful record in identifying and prioritizing portfolios and expanding our commercial partnerships."

Additional details of the agreement may be found in BullFrog AI's Current Report on Form 8-K to be filed with the Securities and Exchange Commission.

**About Major Depressive Disorder (MDD)**

Major depressive disorder (MDD) is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. One of the main causes of disability in the world, MDD has been ranked as the third cause of the burden of disease worldwide in 2008 by World Health Organization, which has projected that this disease will rank first by 2030.

**About BullFrog AI**

BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP<sup>®</sup> platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: <u>https://bullfrogai.com</u>.

**Safe Harbor Statement**

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners' ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

**Contact:**

**Investors:**

CORE IR

<u>ir@bullfrogai.com</u>

**Media:**

CORE PR

<u>pr@bullfrogai.com</u>